CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Swedish Orphan Biovitrum - SOBIs CFD

222.2
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 1.5
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0256 %
Charges from borrowed part ($-1.03)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0256%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0256 %
Charges from borrowed part ($-1.03)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0188%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency SEK
Margin 20%
Stock exchange Sweden
Commission on trade 0%

*Information provided by Capital.com

Swedish Orphan Biovitrum AB (publ) ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* N/A
Open* 221.8
1-Year Change* 35.91%
Day's Range* 220.9 - 220.9
52 wk Range 166.5-245.5
Average Volume (10 days) 0.39935
Average Volume (3 months) 8.19806
Market Cap 66453.1
P/E Ratio 25.6248
Shares Outstanding 295786000
Revenue 17696
EPS 8.37078
Dividend (Yield %) N/A
Beta 0.28573
Next Earnings Date Feb 8, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 28, 2022 222.2 0.4 0.18% 221.8 223.3 220.6
Jun 30, 2022 216.9 0.4 0.18% 216.5 218.4 216.2
Jun 29, 2022 219.6 0.8 0.37% 218.8 220.1 213.4
Jun 28, 2022 219.5 0.5 0.23% 219.0 222.7 218.4
Jun 27, 2022 219.0 1.1 0.50% 217.9 219.9 217.4
Jun 23, 2022 216.2 -0.5 -0.23% 216.7 217.9 215.5
Jun 22, 2022 212.4 -1.3 -0.61% 213.7 214.3 208.8
Jun 21, 2022 214.5 0.1 0.05% 214.4 217.7 213.2
Jun 20, 2022 214.0 4.4 2.10% 209.6 214.8 209.3
Jun 17, 2022 209.3 4.6 2.25% 204.7 209.3 204.3
Jun 16, 2022 206.8 -10.8 -4.96% 217.6 218.6 205.8
Jun 15, 2022 218.7 -2.3 -1.04% 221.0 221.4 217.8
Jun 14, 2022 216.8 -0.9 -0.41% 217.7 218.6 212.4
Jun 13, 2022 213.1 0.2 0.09% 212.9 213.9 208.1
Jun 10, 2022 214.6 9.5 4.63% 205.1 216.6 204.6
Jun 9, 2022 206.9 -8.7 -4.04% 215.6 215.6 206.8
Jun 8, 2022 216.5 -4.5 -2.04% 221.0 221.3 214.0
Jun 7, 2022 219.4 -0.4 -0.18% 219.8 220.6 215.0
Jun 3, 2022 218.5 1.3 0.60% 217.2 218.8 216.7
Jun 2, 2022 217.4 0.3 0.14% 217.1 218.2 215.6

Swedish Orphan Biovitrum Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 5204 6510.83 9138.89 14248 15261 15529
Revenue 5204 6510.83 9138.89 14248 15261 15529
Cost of Revenue, Total 1554 1854 2415.43 3335 3225 3484
Gross Profit 3650 4656.83 6723.47 10913 12036 12045
Total Operating Expense 4071 4910.47 6016.92 9715 10443 11796
Selling/General/Admin. Expenses, Total 1366 1642.93 2047.82 3490 4007 4341
Research & Development 778 901.694 1081.58 1467 1581 1981
Depreciation / Amortization 410 459.565 471.755 1473 1987 1966
Other Operating Expenses, Total -37 -0.264 -6.114 -17 -2 -30
Operating Income 1133 1600.36 3121.97 4533 4818 3733
Interest Income (Expense), Net Non-Operating -85 -66.141 -37.037 -267 -568 -403
Net Income Before Taxes 1048 1532.42 3081.74 4247 4217 3295
Net Income After Taxes 801 1148.61 2417.79 3305 3245 2679
Net Income Before Extra. Items 801 1148.61 2417.79 3305 3245 2679
Net Income 801 1148.61 2417.79 3305 3245 2679
Income Available to Common Excl. Extra. Items 801 1148.61 2417.79 3304 3245 2679
Income Available to Common Incl. Extra. Items 801 1148.61 2417.79 3304 3245 2679
Dilution Adjustment 0 0
Diluted Net Income 801 1148.61 2417.79 3304 3245 2679
Diluted Weighted Average Shares 269.218 270.004 270.604 294.528 297.64 296.799
Diluted EPS Excluding Extraordinary Items 2.97528 4.25406 8.93482 11.2179 10.9024 9.0263
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0 0
Diluted Normalized EPS 2.97528 4.25406 8.94637 11.8996 9.87604 9.19888
Interest Expense (Income) - Net Operating 52.541 2.473 1 42 -2
Other, Net -1.801 -3.196 -19 -33 -35
Unusual Expense (Income) 3.983 -34 -397 56
Total Adjustments to Net Income -1
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 3661 3211 3761 4896 4925
Revenue 3661 3211 3761 4896 4925
Cost of Revenue, Total 726 783 959 1016 1516
Gross Profit 2935 2428 2802 3880 3409
Total Operating Expense 2627 2744 3053 3371 4149
Selling/General/Admin. Expenses, Total 981 1013 1112 1347 1539
Research & Development 471 484 485 554 578
Depreciation / Amortization 450 455 459 477 514
Other Operating Expenses, Total -1 9 38 -23 2
Operating Income 1034 467 708 1525 776
Interest Income (Expense), Net Non-Operating -115 -112 -109 -102 -102
Net Income Before Taxes 919 354 598 1423 674
Net Income After Taxes 696 267 473 1241 543
Net Income Before Extra. Items 696 267 473 1241 543
Net Income 696 267 473 1241 543
Income Available to Common Excl. Extra. Items 696 268 473 1241 543
Income Available to Common Incl. Extra. Items 696 268 473 1241 543
Diluted Net Income 696 268 473 1241 543
Diluted Weighted Average Shares 298.734 296.02 296.654 297.615 297.478
Diluted EPS Excluding Extraordinary Items 2.32983 0.90534 1.59445 4.16982 1.82535
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
Diluted Normalized EPS 2.32983 0.90534 1.59445 4.16982 1.82535
Other, Net -1 -1
Total Adjustments to Net Income 1
Dilution Adjustment 0
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 2911 4157.07 6601.91 7323 8168 8778
Cash and Short Term Investments 786 1478.5 2998.74 737 404 1045
Cash & Equivalents 786 1478.5 2998.74 737 404 1045
Total Receivables, Net 1256 1523.25 2165.16 4625 4523 4105
Accounts Receivable - Trade, Net 769 1459.29 2072.43 4095 4058 3760
Total Inventory 870 1053.27 1284.11 1772 3053 3424
Other Current Assets, Total -1
Total Assets 9974 10902.9 17183.2 45658 48283 48661
Property/Plant/Equipment, Total - Net 121 134.182 136.299 518 534 493
Goodwill, Net 1554 1554.16 1554.16 6678 5873 6288
Intangibles, Net 5252 4890.91 8604.52 30734 32918 32136
Long Term Investments 136 35.155 55.44 50 179 199
Total Current Liabilities 1758 2364.82 6951.07 5741 10443 8761
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 2 99 4126 1882
Other Current Liabilities, Total 1756 887.691 4853.8 1922 1820 1354
Total Liabilities 4609 4202.38 8143.06 28728 28077 25458
Total Long Term Debt 502 5.044 2.991 16461 10445 9024
Long Term Debt 502 5.044 2.991 16141 10137 8777
Other Liabilities, Total 2349 1164.79 525.178 2800 3725 4068
Total Equity 5365 6700.52 9040.1 16930 20206 23203
Other Equity, Total 5365 -144.098 -201 -254 -65
Total Liabilities & Shareholders’ Equity 9974 10902.9 17183.2 45658 48283 48661
Total Common Shares Outstanding 268.78 269.258 269.898 294.3 294.897 295.155
Prepaid Expenses 102.052 153.891 189 188 204
Property/Plant/Equipment, Total - Gross 733.411 730.65 1200 1295 1386
Accumulated Depreciation, Total -599.229 -594.351 -681 -761 -893
Other Long Term Assets, Total 131.429 230.834 355 611 767
Accounts Payable 358.449 486.972 681 569 558
Accrued Expenses 1118.68 1610.3 3039 3928 4967
Deferred Income Tax 667.733 663.821 3726 3464 3605
Common Stock 149.527 149.974 165 167 169
Additional Paid-In Capital 5023.56 5069.25 9697 9816 9945
Retained Earnings (Accumulated Deficit) 1527.44 3964.97 7269 10477 13154
Capital Lease Obligations 320 308 247
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 7969 6689 7392 8778 9363
Cash and Short Term Investments 633 233 212 1045 1063
Cash & Equivalents 633 233 212 1045 1063
Total Receivables, Net 4259 3154 3966 3784 4935
Accounts Receivable - Trade, Net 3336 2337 3085 3439 3748
Total Inventory 3076 3302 3215 3424 3365
Other Current Assets, Total 1 -1
Total Assets 48192 46197 46733 48661 48809
Property/Plant/Equipment, Total - Net 516 491 481 493 380
Goodwill, Net 6099 6006 6141 6288 6398
Intangibles, Net 32879 32271 32040 32136 31866
Long Term Investments 188 184 189 199 121
Other Long Term Assets, Total 541 556 490 767 681
Total Current Liabilities 10330 7952 7910 8761 9056
Accounts Payable 392 434 795 558 545
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 4208 2137 2154 1882 1149
Other Current Liabilities, Total 5730 5381 4961 6321 7362
Total Liabilities 27328 25023 24990 25458 25052
Total Long Term Debt 9501 9682 9563 9024 8624
Long Term Debt 9212 9414 9303 8777 8360
Capital Lease Obligations 289 268 260 247 264
Deferred Income Tax 3517 3473 3448 3605 3461
Other Liabilities, Total 3980 3916 4069 4068 3911
Total Equity 20864 21174 21743 23203 23757
Other Equity, Total 20864 21174 21743 23203 23757
Total Liabilities & Shareholders’ Equity 48192 46197 46733 48661 48809
Total Common Shares Outstanding 294.899 295.145 295.145 295.155 295.155
Prepaid Expenses 525
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line 801 1148.61 2417.79 3304 4217 3295
Cash From Operating Activities 343 1332.94 2090.28 3634 4926 5470
Cash From Operating Activities 31 484.575 188 2023 2006
Amortization 410 1401
Deferred Taxes 165 -103.317 411
Non-Cash Items -765 282.377 -458.309 -5 46 503
Changes in Working Capital -299 -98.047 -250.468 -1665 -1360 -334
Cash From Investing Activities -158 -138.978 -575.357 -21685 -3964 -367
Capital Expenditures -165 -139.445 -577.877 -9746 -3852 -370
Other Investing Cash Flow Items, Total 7 0.467 2.52 -11939 -112 3
Cash From Financing Activities -308 -500 -2.053 15780 -1282 -4474
Financing Cash Flow Items -1 -1 288 -351
Issuance (Retirement) of Stock, Net 24 0
Issuance (Retirement) of Debt, Net -331 -500 -2.053 15781 -1570 -4123
Foreign Exchange Effects 5 -1.258 7.38 9 -13 12
Net Change in Cash -118 692.706 1520.25 -2262 -333 641
Cash Taxes Paid 28.421 506.542 520 918 1124
Cash Interest Paid 13.886 18.259 114 324
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 919 1273 1872 3295 674
Cash From Operating Activities 1699 3092 3349 5470 1644
Cash From Operating Activities 485 976 1470 2006 685
Non-Cash Items -14 69 104 503 395
Cash Taxes Paid 634 796 945 1124 208
Changes in Working Capital 309 774 -97 -334 -110
Cash From Investing Activities -91 -105 -122 -367 -157
Capital Expenditures -91 -107 -125 -370 -157
Other Investing Cash Flow Items, Total 0 2 3 3 0
Cash From Financing Activities -1384 -3163 -3427 -4474 -1491
Financing Cash Flow Items -191 -223 -229 -351 -146
Issuance (Retirement) of Debt, Net -1193 -2940 -3198 -4123 -1345
Foreign Exchange Effects 5 4 7 12 22
Net Change in Cash 229 -172 -193 641 18
Cash Interest Paid 324
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Investor AB Private Equity 34.7297 107594165 0 2022-06-30 LOW
Fjärde AP-Fonden Pension Fund 6.5978 20440422 -92244 2022-06-30 LOW
Swedish Orphan Biovitrum AB (publ) Corporation 3.8602 11959198 3040526 2021-12-31 LOW
Swedbank Robur Fonder AB Investment Advisor/Hedge Fund 2.6898 8333153 -2204444 2022-10-31 LOW
Handelsbanken Kapitalförvaltning AB Investment Advisor/Hedge Fund 2.2043 6829030 -420000 2022-10-31 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 1.7993 5574453 2917298 2022-06-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.6546 5125997 610421 2021-12-31 LOW
SEB Investment Management AB Investment Advisor 1.6015 4961425 1713281 2022-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.5734 4874536 32028 2022-10-31 LOW
Polar Capital LLP Investment Advisor/Hedge Fund 1.5555 4818899 0 2022-10-31 MED
Artisan Partners Limited Partnership Investment Advisor 1.1462 3551047 442904 2022-09-30 LOW
Folksam Group Insurance Company 0.9491 2940428 273386 2022-06-30 LOW
Credit Suisse Asset Management Investment Advisor/Hedge Fund 0.8108 2511775 2403336 2021-12-31 LOW
Lansförsäkringar Fondförvaltning AB Investment Advisor 0.8101 2509765 100000 2022-10-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.7643 2367804 6700 2022-10-31 LOW
Tredje AP Fonden Pension Fund 0.6739 2087876 -361476 2022-06-30 LOW
Brown Brothers Harriman & Company Bank and Trust 0.6652 2060835 2060835 2022-06-30 LOW
Livförsäkringsbolaget Skandia, ömsesidigt Insurance Company 0.6003 1859700 -817173 2022-06-30 LOW
Storebrand Kapitalforvaltning AS Investment Advisor 0.5057 1566720 95295 2022-10-31 LOW
TIN Fonder Investment Advisor 0.4842 1500000 1500000 2022-06-30 MED

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Sobi Company profile

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Swedish Orphan Biovitrum AB (publ) revenues increased 2% to SEK15.53B. Net income decreased 17% to SEK2.68B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Sales and Administration increase of 11% to SEK4.45B (expense). Basic Earnings per Share excluding Extraordinary Items decreased from SEK11.01 to SEK9.08.

Equity composition

12/2009, Rights Issue, 2 new shares for every share held @ SEK 15 (Factor: 1.99722). 5/2011, Rights Issue, 1 new share for every 4 shares held @ SEK12 (Factor: 1.11749).

Industry: Biopharmaceuticals

Tomtebodavägen 23A
SOLNA
STOCKHOLM 171 65
SE

Income Statement

People also watch

Natural Gas

6.06 Price
+5.510% 1D Chg, %
Long position overnight fee 0.0546%
Short position overnight fee -0.0818%
Overnight fee time 22:00 (UTC)
Spread 0.006

BTC/USD

17,030.05 Price
+0.900% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 66.00

US100

11,624.40 Price
+1.150% 1D Chg, %
Long position overnight fee -0.0164%
Short position overnight fee 0.0059%
Overnight fee time 22:00 (UTC)
Spread 1.9

Oil - Crude

71.98 Price
-0.580% 1D Chg, %
Long position overnight fee -0.0086%
Short position overnight fee -0.0054%
Overnight fee time 22:00 (UTC)
Spread 0.03

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading